Oragenics appoints CFO Janet Huffman as interim CEO; provides ONP-002 Phase II timeline

ORAGENICS INC

CFO Janet Huffman named interim CEO, retaining CFO role; board expresses confidence in her leadership.
Company raised $4M in September 2024; progress includes improved ONP-002 formulation and device prototyping.
Phase II trial in Australia: first patient dosing targeted by end of Q1 2025 or early Q2 2025.
IND package for U.S. Phase IIb clinical trial targeted for Q3 2025.
Spray-dry campaign completed to ensure sufficient drug-device units for upcoming trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.